GlobeNewsWire
08 Jun 2026, 07:00 UTC · 5h ago
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
GlobeNewsWire
08 Jun 2026, 07:00 UTC · 5h ago
Story key points
3 claims · impact-rated
Novartis will present Phase III results from the RemIND trial for Rhapsido (remibrutinib) in chronic inducible urticaria (CIndU) at the EAACI Congress 2026. — Phase III data is a primary catalyst for regulatory approval and commercialization of a new drug indication.
+0.60Novartis will release extension data from the Phase IIIb REMIXED trial for Rhapsido in chronic spontaneous urticaria (CSU). — Long-term extension data validates the durability and safety profile of the drug, supporting its competitive positioning.
+0.40Novartis will present early Phase II dose-response analysis for Rhapsido in treating food allergies. — Early phase data indicates potential for pipeline expansion into new therapeutic areas, though it carries higher risk than Phase III.
+0.30Ticker attribution
Continue reading
6 related stories
Top 2 movers · tap to explore
Model heads
The company is presenting promising Phase III clinical trial data and expanding the potential use cases for its drug Rhapsido.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
4 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
GlobeNewsWire
7h ago
